Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of bevacizumab + lomustine versus lomustine in first recurrent glioblastoma
NL-OMON39944Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing Lomustine + bevacizumab with Lomustine (2 arms). Primary endpoint: Overall survival. Started Nov 2011; status: active, not recruiting.
02
Drugs
bevacizumablomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON39944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39944.